U.S. markets closed
  • S&P 500

    4,210.24
    +87.77 (+2.13%)
     
  • Dow 30

    33,309.51
    +535.10 (+1.63%)
     
  • Nasdaq

    12,854.80
    +360.88 (+2.89%)
     
  • Russell 2000

    1,969.25
    +56.36 (+2.95%)
     
  • Crude Oil

    91.56
    +1.06 (+1.17%)
     
  • Gold

    1,787.80
    -6.20 (-0.35%)
     
  • Silver

    20.57
    +0.08 (+0.41%)
     
  • EUR/USD

    1.0303
    +0.0085 (+0.83%)
     
  • 10-Yr Bond

    2.7860
    -0.0110 (-0.39%)
     
  • GBP/USD

    1.2219
    +0.0142 (+1.18%)
     
  • USD/JPY

    132.8910
    -2.2250 (-1.65%)
     
  • BTC-USD

    23,693.29
    +576.46 (+2.49%)
     
  • CMC Crypto 200

    558.33
    +27.11 (+5.10%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS: ALPMF)

  • The data were presented at the American Society for Cell and Gene Therapy (ASGCT) meeting.

  • Data Highlights:

    • HiTs are CD8 and HLA-independent and kill mesothelin expressing human tumor cells.

    • Data demonstrate that the mesothelin HiT is not dependent on CD8 to kill target cells, and CD4 cells expressing the HiT are cytotoxic towards tumor cells.

    • Data from additional in vitro experiments show that Adaptimmune's HiT is not neutralized by soluble mesothelin, unlike the TRuC construct.

    • HiT T-cells targeting mesothelin induced complete tumor regression in a mouse xenograft tumor model and outperformed a comparator TRuC construct.

  • Price Action: ADAP shares are up 2.1% at $4.82 during the market trading session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.